SLC5A2 and type 2 diabetes mellitus: The recent DAPA-HF trial suggests that glucose-lowering plays little part in the amelioration of heart failure, at least, by SGLT2 inhibitors, as almost identical risk reductions for heart failure were seen in individuals with and without T2D (66).